Tumor necrosis factor receptor superfamily 1A-associated periodic syndrome (TRAPS)

被引:6
作者
Hentgen, V
Granel, B
Dodé, C
Cuisset, L
Delpech, M
Grateau, G [1 ]
机构
[1] Inst Cochin, CNRS, UMR 8104,Equipe Genet & Physiopathol Malad Inflam, INSERM,U567,Dept Genet Dev & Pathol Mol, Paris, France
[2] Ctr Hosp Intercommunal, Serv Pediat, Creteil, France
[3] Hop Enfants La Timone, Serv Med Interne, F-13385 Marseille, France
[4] Hop Cochin, AP HP, Biochim Genet Lab, F-75674 Paris, France
[5] Assistance Publ Hop Paris AP HP, Hotel Dieu, Serv Med Interne, F-75181 Paris, France
来源
REVUE DE MEDECINE INTERNE | 2003年 / 24卷 / 12期
关键词
TRAPS; tumor necrosis factor; TNF receptor; amyloid;
D O I
10.1016/S0248-8663(03)00216-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose. - Tumor necrosis factor receptor superfamily I A associated periodic syndrome (TRAPS) belongs to the group of hereditary fever syndromes, also called hereditary auto-inflammatory syndromes. Current knowledge and key points. - The diagnosis of TRAPS should be evoked in presence of the following clinical signs, whatever the population of the affected patients. TRAPS acute inflammatory access, of 1 to 3 weeks' duration, is characterised by the presence of fever, abdominal pain, myalgias, various types of skin rash including erysepela-like erythema. Long term inflammatory response can lead to AA amyloidosis. Genetic testing will confirm the diagnosis when showing a mutation in the extracellular part of the TNFRSF/A receptor. Therapeutic management of TRAPS is not definitely established. Daily colchicine does not seem to prevent efficiently inflammatory attacks. Corticosteroids, in contrast can attenuate the intensity and diminish the duration of attacks. Future prospects and projects. - The value of biological agents that inhibits TNF action is not yet completely determined in TRAPS. Mechanisms of the disease are not yet elucidated. In some families with specific mutations, a relative soluble TNF receptor deficiency has been found in the plasma. However this mechanism does not account for what is observed in other kindreds. (C) 2003 Publie par Editions scientifiques et medicales Elsevier SAS.
引用
收藏
页码:781 / 785
页数:5
相关论文
共 22 条
[1]   The tumor-necrosis-factor receptor-associated periodic syndrome:: New mutations in TNFRSF1A, ancestral origins, genotype-phenotype studies, and evidence for further genetic heterogeneity of periodic fevers [J].
Aksentijevich, I ;
Galon, J ;
Soares, M ;
Mansfield, E ;
Hull, K ;
Oh, HH ;
Goldbach-Mansky, R ;
Dean, J ;
Athreya, B ;
Reginato, AJ ;
Henrickson, M ;
Pons-Estel, B ;
O'Shea, JJ ;
Kastner, DL .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 69 (02) :301-314
[2]   PERIODIC FEVER - OCCURRENCE IN 5 GENERATIONS [J].
BOURONCLE, BA ;
DOAN, CA .
AMERICAN JOURNAL OF MEDICINE, 1957, 23 (03) :502-506
[3]   Tumor necrosis factor antagonist therapy and lymphoma development - Twenty-six cases reported to the Food and Drug Administration [J].
Brown, SL ;
Greene, MH ;
Gershon, SK ;
Edwards, ET ;
Braun, MM .
ARTHRITIS AND RHEUMATISM, 2002, 46 (12) :3151-3158
[4]   The enlarging clinical, genetic, and population spectrum of tumor necrosis factor receptor-associated periodic syndrome [J].
Dodé, C ;
André, M ;
Bienvenu, T ;
Hausfater, P ;
Pêcheux, C ;
Bienvenu, J ;
Lecron, JC ;
Reinert, P ;
Cattan, D ;
Piette, JC ;
Szajnert, MF ;
Delpech, M ;
Grateau, G .
ARTHRITIS AND RHEUMATISM, 2002, 46 (08) :2181-2188
[5]  
Dodé C, 2000, ARTHRITIS RHEUM-US, V43, P1535, DOI 10.1002/1529-0131(200007)43:7<1535::AID-ANR18>3.0.CO
[6]  
2-C
[7]   Medical progress: Hereditary periodic fever. [J].
Drenth, JPH ;
van der Meer, JWM .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (24) :1748-1757
[8]   Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome [J].
Drewe, E ;
McDermott, EM ;
Powell, RJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (14) :1044-1045
[9]   Prospective study of anti-tumour necrosis factor receptor superfamily 1B fusion protein, and case study of anti-tumour necrosis factor receptor superfamily 1A fusion protein, in tumour necrosis factor receptor associated periodic syndrome (TRAPS): clinical and laboratory findings in a series of seven patients [J].
Drewe, E ;
McDermott, EM ;
Powell, PT ;
Isaacs, JD ;
Powell, RJ .
RHEUMATOLOGY, 2003, 42 (02) :235-239
[10]   TNFRSF1A mutations and autoinflammatory syndromes [J].
Galon, J ;
Aksentijevich, I ;
McDermott, MF ;
O'Shea, JJ ;
Kastner, DL .
CURRENT OPINION IN IMMUNOLOGY, 2000, 12 (04) :479-486